OptiBiotix Health PLC Total Voting Rights
October 24 2024 - 1:00AM
RNS Regulatory News
RNS Number : 3839J
OptiBiotix Health PLC
24 October 2024
OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the
Group")
Total Voting Rights
OptiBiotix
Health plc (AIM:
OPTI), a
life sciences
business developing compounds to
tackle obesity, high cholesterol, diabetes and skincare confirms that its
issued share capital and total voting rights is
97,943,161.
This figure may be used by shareholders in the
Company as the denominator for the calculations by which they will
determine if they are required to issue a notification of their
interest in, or of a change in their interest in the share capital
of the Company under the FCA's Disclosure Guidance and Transparency
Rules.
The Company is aware that an invalid allotment
of 3,125,000 shares ("Invalid Allotment Shares") was entered onto
its register in August 2024. This allotment was made as a
result of an administrative error by the Company. The Company
is in the process of correcting this error. The Invalid
Allotment Shares have not been notified to the market nor have they
been admitted to trading on AIM.
For further
information, please contact: OptiBiotix Health
plc
|
www.optibiotix.com
|
Neil Davidson, Chairman
|
Contact via Walbrook
below
|
Stephen O'Hara, Chief Executive
|
|
|
|
Cairn
Financial Advisers LLP (NOMAD)
|
Tel: 020 7213
0880
|
Liam Murray / Jo Turner / Ludovico
Lazzaretti
|
|
|
|
Peterhouse
Capital Limited (Broker)
|
Tel: 020 7220
9797
|
Duncan Vasey / Lucy Williams
|
|
|
|
Walbrook PR
Ltd
|
Mob: 07876 741
001
|
Anna Dunphy
|
|
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI),
which was formed in March 2012, brings science to the development
of compounds which modify the human microbiome - the collective
genome of the microbes in the body - in order to prevent and manage
human disease and promote wellness.
OptiBiotix has an extensive R&D
programme working with leading academics in the development of
microbial strains, compounds, and formulations which are used as
active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements
with OptiBiotix to incorporate their human microbiome modulators
into a wide range of food products and drinks.
OptiBiotix is also developing its
own range of consumer supplements and health products. The
Company's current areas of focus include obesity, cardiovascular
health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
TVRBCBDGIXDDGSX
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Dec 2023 to Dec 2024